CD8A and cancer: This work demonstrated that the immunization of mice with non-replicable (treated with MMC or irradiated) MC38 CRC cells with a novel protozoan parasite-derived protein adjuvant, rGRA6Nt, potently activates the cancer cell-specific CD8+ cytotoxic T cells and IFN-γ-producing CD8+ T cells and inhibits the growth of tumors of the identical cancer cells after its challenge implantation.